logo
Plus   Neg
Share
Email

Jazz Pharma: FDA Grants Priority Review For Lurbinectedin

PharmaMar and Jazz Pharmaceuticals plc (JAZZ) announce that a New Drug Application for Lurbinectedin has been accepted by FDA and granted Priority Review for Relapsed Small Cell Lung Cancer.

The Priority Review by the FDA is for patients with Small Cell Lung Cancer (SCLC) who have progressed after prior platinum-containing therapy.

A Prescription Drug User Fee Act or PDUFA date is set for August 16, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the current state of the COVID-19 pandemic in the U.S. is "really not good." The U.S. is the country worst-affected by the coronavirus and has recently seen a surge in coronavirus infections as lockdown restrictions are eased. Granules Pharmaceuticals, Inc. recalled twelve (12) lots of type 2 diabetes medication Metformin hydrochloride Extended-Release, in the form of oral film-coated tablets, for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Palantir Technologies Inc., the Silicon Valley big data analytics company that has handled U.S. government's certain sensitive projects, said it has confidentially filed documents with the Securities and Exchange Commission to go public. In a statement, the company said the proposed public listing of its Class A common stock is expected to take place after the SEC completes its review process.
RELATED NEWS
Follow RTT